Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.

PloS one - 1 Jan 2014

Tresukosol Damrus, Suktitipat Bhoom, Hunnangkul Saowalak, Kamkaew Ruttakarn, Poldee Saiphon, Tassaneetrithep Boonrat, Likidlilid Atip

Abstract excerpt

Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to active thiol metabolite with inconsistent resul...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Diphosphate
Share to Aryldialkylphosphatase
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Artery Disease

Share to Cytochrome P-450 CYP2C19

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 25329996
DOI: 10.1371/journal.pone.0110188
PMCID: PMC4199712

Genes

PON1
CAD

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25329996-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.PMID 25329996Read ↗

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.Semantic proximity Read ↗

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.Semantic proximity Read ↗

Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.Semantic proximity Read ↗

Genetic and nongenetic factors influencing the response to clopidogrel.Semantic proximity Read ↗

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.Semantic proximity Read ↗

Pharmacogenomics of clopidogrel: evidence and perspectives.Semantic proximity Read ↗

The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.Semantic proximity Read ↗

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.Semantic proximity Read ↗

Genetic determinants of on-clopidogrel high platelet reactivity.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.Semantic proximity Read ↗

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.